Abstract
Up to 10% of primary colon cancers are attached to adjacent organs or other anatomical structures. True invasion, however, occurs in approximately 50%, with the remaining cases secondary to adhesions from tumour-related inflammation and contained tumour perforation. The most commonly involved organs and structures include small bowel, urinary bladder and abdominal wall. The sigmoid colon is the most common primary tumour site with advanced disease [1]. Organs less commonly involved with locally invasive colon cancer are the liver, spleen, pancreas, stomach and gallbladder. Nevertheless, when a structure in the abdomen is involved with the primary tumour, regardless of the anatomical site, it must be included en bloc with the primary specimen. Attempts to “reduce” radicality by shaving off adherent structures from the primary tumour are likely to result in a palliative situation. Situations involving an R1 (microscopically positive margins) resection, even when subsequent resection is planned, are associated with significantly higher risks of local recurrence including peritoneal carcinomatosis. Local residual cancer (R1, 2 resection) is a significant predictor of survival, with a median survival of 12 months [2–4]. This applies not only to local recurrence but also to distant metastases [5].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Croner RS, Merkel S, Papadopoulos T, Schellerer V, Hohenberger W, Goehl J. Multivisceral resection for colon carcinoma. Dis Colon Rectum. 2009;52:1381–6.
Hermanek P. Prognostic factor research in oncology. J Clin Epidemiol. 1999;52:371–4.
Hermanek P, Wittekind C. Residual tumour (R) classification and prognosis. Semin Surg Oncol. 1994;10:12–20.
Newland RC, Dent OF, Chapuis PH, Bokey EL. Clinicopathologically diagnosed residual tumour after resection for colorectal cancer. A 20-year prospective study. Cancer. 1993;72:1536–42.
Sjövall A1, Granath F, Cedermark B, Glimelius B, Holm T. Loco-regional recurrence from colon cancer: a population-based study. Ann Surg Oncol. 2007;14:432–40.
Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, De Forges H, Stanbury T, Paineau J, Glehen O. UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. Abstract. ASCO. 2018;36:LBA3503.
Cirocchi R, Partelli S, Castellani E, Renzi C, Parisi A, Noya G, et al. Right hemicolectomy plus pancreaticoduodenectomy vs partial duodenectomy in treatment of locally advanced right colon cancer invading pancreas and/or only duodenum. Surg Oncol. 2014;23:92–8.
Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Gaertner, W.B., Kuzu, M.A., Rothenberger, D.A. (2021). Colon Cancer: Multivisceral Resection. In: Hohenberger, W., Parker, M. (eds) Lower Gastrointestinal Tract Surgery. Springer Surgery Atlas Series. Springer, Cham. https://doi.org/10.1007/978-3-030-60827-9_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-60827-9_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-60826-2
Online ISBN: 978-3-030-60827-9
eBook Packages: MedicineMedicine (R0)